Skip to main content
Signal8
Launch Terminal

Protagonist Therapeutics, Inc (PTGX)

Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics maintains a licensing and collaborative agreement with Janssen Biotech, Inc. Founded in 2006, the company's headquarters are located in Newark, California.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Protagonist Therapeutics, Inc. logo

Protagonist Therapeutics, Inc.

NASDAQ:PTGXHealthcare
+0.35%$144.85
AH$144.85+0.00%vs close
Mkt Cap$9.37B
Float61.21M
O/S64.71M
Vol
$ Vol
RVOL
Inst Own-
SI16.8%
Earnings
Dilution
Protagonist Therapeutics, Inc. logoNASDAQ:PTGX$144.85+0.35%
Phase Distribution
13 lead-sponsored trials·2 active·10 completed
Phase 14
Phase 27
Phase 32
(1 more as collaborator)
Status Overview
Active, not recruiting2
Completed10
Stopped1

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Sponsor role
Status
Phase
  • Phase 3
    Active, not recruiting

    A Study of Rusfertide in Adults With Polycythemia Vera (PV)

    Rusfertide, Placebo

    Polycythemia Vera

    Enrollment
    293
    Start
    Apr 2022
    Primary Completion
    Feb 2025
    Completion
    Aug 2028est.
    NCT05210790
  • Phase 3
    Active, not recruiting

    Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera

    Open-label rusfertide

    Polycythemia Vera

    Enrollment
    46
    Start
    Jan 2024
    Primary Completion
    Apr 2026est.
    Completion
    Apr 2027est.
    NCT06033586
  • Phase 2
    Terminated

    Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis

    PTG-100, Placebo

    Ulcerative Colitis

    Enrollment
    98
    Start
    Dec 2016
    Primary Completion
    Mar 2018
    Completion
    Mar 2018
    NCT02895100
  • Phase 2
    Completed

    Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia

    PTG-300

    β-thalassemia, Ineffective Erythropoiesis +1

    Enrollment
    63
    Start
    Dec 2018
    Primary Completion
    Jul 2020
    Completion
    Jul 2020
    NCT03802201
  • Phase 2
    Completed

    Safety Study for Beta Thalassemia Subjects on PTG-300

    PTG-300

    β-thalassemia, Ineffective Erythropoiesis

    Enrollment
    34
    Start
    May 2019
    Primary Completion
    Jul 2020
    Completion
    Jul 2020
    NCT04054921
  • Phase 2
    Completed

    Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

    PTG-300, Placebo

    Polycythemia Vera

    Enrollment
    70
    Start
    Oct 2019
    Primary Completion
    Feb 2023
    Completion
    Jun 2024
    NCT04057040
  • Phase 2
    Completed

    PTG-300 in Subjects With Hereditary Hemochromatosis

    PTG-300

    Hereditary Hemochromatosis

    Enrollment
    16
    Start
    Mar 2020
    Primary Completion
    Oct 2021
    Completion
    Feb 2022
    NCT04202965
  • Phase 2
    Completed

    PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)

    PN-943, Placebo

    Ulcerative Colitis Chronic Moderate, Ulcerative Colitis Chronic Severe

    Enrollment
    169
    Start
    Aug 2020
    Primary Completion
    Feb 2023
    Completion
    Feb 2023
    NCT04504383
  • Phase 2
    Completed

    PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit

    PTG-300

    Polycythemia Vera

    Enrollment
    20
    Start
    Feb 2021
    Primary Completion
    Mar 2023
    Completion
    Mar 2023
    NCT04767802
  • Phase 1
    Completed

    Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers

    PTG-300

    Healthy Volunteers

    Enrollment
    12
    Start
    Sep 2020
    Primary Completion
    Jan 2021
    Completion
    Jun 2021
    NCT04516382
  • Phase 1
    Completed

    Pharmacokinetics of PN-235 in Healthy Volunteers

    PN-235, Placebo

    Healthy Volunteers

    Enrollment
    107
    Start
    Nov 2020
    Primary Completion
    Sep 2021
    Completion
    Oct 2021
    NCT04621630
  • Phase 1
    Completed

    Pharmacokinetics of PN-232 in Healthy Volunteers

    PN-232, Placebo

    Healthy Subjects

    Enrollment
    48
    Start
    May 2021
    Primary Completion
    Dec 2021
    Completion
    Jun 2022
    NCT04819620
  • Phase 1
    Completed

    Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.

    PN-881 Oral Solution, PN-881 Oral Tablet

    Healthy Volunteer

    Enrollment
    146
    Start
    Oct 2025
    Primary Completion
    Jul 2026
    Completion
    Jul 2026
    NCT07153146
Search ClinicalTrials.gov for “Protagonist Therapeutics”